Financial HealthThe company ended with CHF 146M in cash, which should provide funding into 1Q27.
PartnershipsAC Immune has partnered with Dr. Klaus Gerwert’s team to exploit technology used for Alzheimer's disease to detect alpha-synuclein, which may be beneficial for measuring the efficacy of the vaccine.
Vaccine EfficacyThe development of a safe vaccine against alpha-synuclein allows potential application in preclinical or asymptomatic Parkinson’s disease patients.